First-line trastuzumab (H), oral vinorelbine (NVBo) and capecitabine (X) combination therapy for HER2-positive metastatic breast cancer (MBC): efficacy and safety in a multinational phase II study.

Details

Language :

English

ISSN :

13596349

Volume :

6

Issue :

7

Database :

Supplemental Index

Journal :

EJC Supplements

Publication Type :

Academic Journal

Accession number :

32054554

Full Text :

https://doi.org/10.1016/S1359-6349(08)70894-2